Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18230965 | 0.77 | FDPS (0.55) | METAP1ACP3ANPEPERAP2CA12 | |
| SCHEMBL1243144 | 0.74 | MMP1 (0.34) | METAP1MMP1MMP2 | |
| SCHEMBL7431441 | 0.72 | METAP1 (0.51) | METAP1ACP3ANPEPERAP2 | |
| SCHEMBL7435009 | 0.72 | METAP1 (0.51) | METAP1ACP3ANPEPERAP2 | |
| SCHEMBL26076509 | 0.71 | CPN1 (0.44) | — | |
| SCHEMBL13327340 | 0.70 | FDPS (0.52) | METAP1ACP3ANPEPERAP2CA12 | |
| SCHEMBL9170443 | 0.69 | METAP1 (0.44) | METAP1ACP3ANPEPERAP2CA12 | |
| SCHEMBL7784263 | 0.69 | TP53 (0.48) | — | |
| SCHEMBL12050314 | 0.69 | TP53 (0.43) | — | |
| SCHEMBL25852161 | 0.69 | TP53 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-7488739-B2 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20060148806-A1 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1650192-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | METAP1 3974/4885ACP3 2000/4885ANPEP 2788/4885 |
| US-20060148806-A1 | Quinolone derivative or salt thereof | THPO, ABL1, GMPS | METAP1 3974/4885ACP3 2000/4885ANPEP 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.